$300 Million Offering Announced
Apogee Therapeutics, Inc. (NASDAQ: APGE), a pioneering biotechnology firm, has recently unveiled a public offering aiming to raise $300 million. This substantial move involves the pricing of approximately 6,951,221 shares of their common stock, valued at $41.00 per share. Additionally, they will offer pre-funded warrants for 365,853 shares at a price of $40.99999 each. These warrants provide immediate exercise capabilities, making it an attractive option for certain investors.
Details of the Offering
The public offering by Apogee is set to close shortly, subject to standard closing conditions. The company has also granted underwriters an option, exercisable within the next 30 days, to purchase an additional 1,097,561 shares at the same public offering price. This additional capacity could amplify the financing, providing further resources to fuel company growth.
Key Underwriters Engage
Esteemed financial institutions are backing this initiative. Jefferies, BofA Securities, Guggenheim Securities, and TD Cowen are spearheading the underwriting process as joint book-running managers, establishing a solid financial framework for Apogee's public offering.
Regulatory Compliance in Focus
Regulatory compliance is a priority for Apogee. An automatic shelf registration statement was filed with the Securities and Exchange Commission (SEC) back in August 2024. A future prospectus will include comprehensive details regarding this offering, ensuring transparency and adherence to SEC guidelines.
About Apogee Therapeutics
Innovative Biotechnology Solutions
Apogee Therapeutics is at the forefront of biotechnology, focusing on advanced biologics geared toward treating inflammatory and immunological conditions. The company's mission spans across various ailments, including Atopic Dermatitis, asthma, Eosinophilic Esophagitis, and Chronic Obstructive Pulmonary Disease (COPD). With a well-structured portfolio, Apogee aims to deliver therapies that address the unmet needs within these critical markets.
Pipeline of Promising Drugs
Apogee Therapeutics has developed an impressive pipeline, including its most advanced candidate, APG777. The treatment is poised to serve the Atopic Dermatitis market, which remains largely untapped. By leveraging advanced antibody engineering and targeting established mechanisms of action, Apogee is confident in achieving superior therapeutic outcomes compared to existing treatments.
Investors and Media Relations
Investor interest is critical for biotechnology companies to thrive. Apogee's VP of Investor Relations, Noel Kurdi, serves as an important point of contact for any inquiries related to this public offering or the company's financial health. Investors or stakeholders looking for information can reach out directly to Noel at Noel.Kurdi@apogeetherapeutics.com.
Frequently Asked Questions
What is the purpose of Apogee’s public offering?
The offering aims to raise funds to advance Apogee's innovative drug development pipelines.
Who are the underwriters of this offering?
Jefferies, BofA Securities, Guggenheim Securities, and TD Cowen are acting as joint managers for this public offering.
What types of securities are being offered?
The offering includes common shares and pre-funded warrants for potentially more capital leverage.
How does Apogee plan to utilize the raised funds?
Funds will likely support continued research and development of their leading drug candidates and enhance their product pipelines.
What is Apogee’s main focus area in biotechnology?
Apogee focuses on developing novel biologics for treating significant inflammatory and immunology disorders, including Atopic Dermatitis and asthma.
